January 16, 2019

CooperVision’s landmark MiSight® 1 day study releases four-year results

— Newly released four-year study data shows the significant impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later. CooperVision presented its long-term study’s latest results during the British Contact Lens Association’s Asia conference in Singapore in September 2018, at which the globally increasing prevalence of myopia was among the most widely discussed issues.

The ongoing international clinical trial is assessing the efficacy of the specially-designed, dual-focus myopia control soft contact lens, MiSight® 1 day, in reducing both the rate of progression and ocular axial elongation in juvenile-onset myopia.

“The four-year results on the efficacy of our innovative myopia control lens represent a landmark in slowing myopia progression. The treatment is continuing to work for children who have been wearing MiSight 1 day for the entire study, and their axial length progression in this past year has slowed further. This illustrates the benefits of beginning myopia management as early as possible to maximise the benefit,” said Paul Chamberlain, Director of Research Programs for CooperVision.

After three years, myopia progression slowed in children wearing MiSight 1 day by 59% as measured by mean cycloplegic spherical equivalent refractive error (SERE) and by 52% as measured by mean axial elongation of the eye when compared to children in the control group wearing a single vision 1-day contact lens made from the same material.

After three years, children in the control group were refitted with MiSight 1 day but still followed separately. Use of MiSight 1 day — which has alternating visual correction and treatment zones — was effective in slowing myopia progression in both groups:

  • There was a significant reduction in myopic progression for the previous single vision 1-day wearers, indicating that MiSight 1 day is also effective when beginning myopia management at an older age.
  • There were no significant differences between groups for change in SERE and axial length over 12 months.
  • Axial length growth of 0.07mm in the MiSight 1day group and 0.06mm in the previous control group, compared to 0.10mm seen in the MiSight 1 day group in year three, represents further myopia slowing as the children age.
  • There were no significant differences in myopia progression rates for two demographically matched populations in their first versus fourth years of MiSight 1 day lens wear.

No other prospective randomised controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a 1-day soft contact lens over four years.

“The four-year results are another significant finding for CooperVision and the entire optical industry on the capability to slow the progression of myopia in children. Though children benefit at whatever age the treatment is started, the sooner their myopia is managed with MiSight 1 day, the more effect and benefit they receive in reducing final levels and the future risk of related vision impairment issues,” said Stuart Cockerill, Senior Director, Myopia Management.

# # #

1MiSight® 1 Day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in the United States.

2Holden et al, Ophthalmology 2016.

About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Media Contact

Joe Tanner, Professional Services Manager, ANZ

Ph: +61 457 800 468